

Instructions For Use A00107-IFU-IVD

Rev. Date: Oct. 8, 2012

Revision: 1

Page 1 of 2

P.O. Box 3286 - Logan, Utah 84323, U.S.A. - Tel. (800) 729-8350 - Tel. (435) 755-9848 - Fax (435) 755-0015 - www.scytek.com

CA19-9; Clone 121SLE (Ready-To-Use)

Availability/Contents: <u>Item #</u> <u>Volume</u>

 A00107-0002
 2 ml

 A00107-0007
 7 ml

 A00107-0025
 25 ml

Description:

Specificity:

Species: Mouse

Immunogen: Precipitin lines obtained after immunodiffusion using MAb 116-NS-19-9 and mucins isolated

from an ovarian cyst of a Lewis A+B- patient (0Le) were used as immunogen for this CA19-9

antibody.

Clone: 121SLE Isotype: IgM, Kappa

Format: This antibody has been pretitered and quality controlled to work on formalin-fixed paraffin-

embedded as well as acetone fixed cryostat tissue sections. No further titration is required. CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewis^a structure which is synthesized from type 1 blood group precursor chains and is

present in individuals expressing the Lewis^a and/or Lewis^b blood group antigens. In normal tissues, sialyl Lewis^a antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can

predict recurrence of disease prior to radiographic or clinical findings.

Species Reactivity: Human

Cellular Localization: Lumenal surface and cytoplasm.
Titer/Working Dilution: No further dilution is required.
Microbiological State: This product is not sterile.

Uses/Limitations: Not to be taken internally.

For In Vitro Diagnostic Use.

This product is intended for qualitative immunohistochemistry with normal and neoplastic formalin-fixed, paraffin-embedded tissue sections, to be viewed by light microscopy.


Do not use if reagent becomes cloudy. Do not use past expiration date. Use caution when handling reagents.

Non-Sterile.

Ordering Information and Current Pricing at www.scytek.com

Storage: 2° C

ScyTek Laboratories, Inc. 205 South 600 West Logan, UT 84321 U.S.A.



 ϵ

EC REP EmergoEurope (31)(0) 70 345-8570 Molsnstraat 15 2513 BH Hague, The Netherlands



Instructions For Use A00107-IFU-IVD

Rev. Date: Oct. 8, 2012

Revision: 1

Page 2 of 2

P.O. Box 3286 - Logan, Utah 84323, U.S.A. - Tel. (800) 729-8350 - Tel. (435) 755-9848 - Fax (435) 755-0015 - www.scytek.com

Procedure:

- Tissue Section Pretreatment: Staining of formalin fixed, paraffin embedded tissue sections is enhanced by pretreatment with Citrate Plus (ScyTek catalog# CPL500) or 10mM citrate buffer, pH 6.0 (ScyTek Catalog# CBB500, see IFU for instructions).
- Primary Antibody Incubation Time: We suggest an incubation period of 30 minutes at room temperature.
 However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the user.
- 3. **Visualization:** For maximum staining intensity we recommend the "UltraTek HRP Anti-Polyvalent Lab Pack" (ScyTek catalog# UHP125, see IFU for instructions) combined with the "DAB Chromogen/Substrate Bulk Pack (High Contrast)" (ScyTek catalog# ACV500, see IFU for instructions).

Precautions:

Contains Sodium Azide as a preservative (0.09% w/v).

Do not pipette by mouth.

Avoid contact of reagents and specimens with skin and mucous membranes.

Avoid microbial contamination of reagents or increased nonspecific staining may occur.

This product contains no hazardous material at a reportable concentration according to U.S. 29 CFR 1910.1200,

OSHA Hazardous Communication Standard and EC Directive 91/155/EC.

References:

- 1. Nomoto S; Nakao A; Ichihara T; Takagi H. Hepato-Gastroenterology, 1995 Sep-Oct, 42(5):717-23.
- Webb A; Scott-Mackie P; Cunningham D; Norman A; Andreyev J; O'Brien M; Bensted J. Éuropean Journal of Cancer, 1996 Jan, 32A(1):63-8.
- 3. Tsuruta T; Ogawa A; Ishii K; Ikado S. Urologia Internationalis, 1997, 58(1):20-4.
- 4. van den Bosch RP; van Eijck CH; Mulder PG; Jeekel J. Hepato-Gastroenterology, 1996 May-Jun, 43(9):710-3.
- 5. Kodera Y; Yamamura Y; Torii A; Uesaka K; Hirai T; Yasui K; Morimoto T; Kato T; Kito T. American J of Gastroenterology, 1996, 91:49-53.
- 6. Furuya N; Kawa S; Hasebe O; Tokoo M; Mukawa K; Maejima S; Oguchi H. British Journal of Cancer, 1996 Feb, 73(3):372-6.
- 7. Wang FM; Tsai LC; Chang ZN; Han SH; Tsao D. Proceedings of the National Science Council, Republic of China. Part B, Life Sciences, 1985 Apr, 9(2):119-25.

Warranty:

No products or "Instructions For Use (IFU)" are to be construed as a recommendation for use in violation of any patents. We make no representations, warranties or assurances as to the accuracy or completeness of information provided on our IFU or website. Our warranty is limited to the actual price paid for the product. ScyTek Laboratories, Inc. is not liable for any property damage, personal injury, time or effort or economic loss caused by our products. Immunohistochemistry is a complex technique involving both histological and immunological detection methods. Tissue processing and handling prior to immunostaining can cause inconsistent results. Variations in fixation and embedding or the inherent nature of the tissue specimen may cause variations in results. Endogenous peroxidase activity or pseudoperoxidase activity in erythrocytes and endogenous biotin may cause non-specific staining depending on detection system used.

